Clinical study and mechanism exploration of the efficacy and safety of the Wenyang Tongxia method in the maintenance stage of metastatic colorectal cancer treatment

Xi yuan Hospital of CACMS0 个研究点开始时间: 待定最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•(1) patients aged 18-80, gender not limited, (2) pathologically diagnosed with colorectal cancer with clinical stage IV, (3) those who intended to receive maintenance therapy after criteria according to NCCN or CSCO colorectal cancer guidelines, (4) those with Eastern Cooperative Oncology Group (ECOG) score of 0-2, (5) those with expected survival =3 months, (6)those with measurable lesions according to RECIST 1.1 criteria, (7)those with no severe cardiac, pulmonary, hepatic, or renal function abnormalities, (8) those with normal coagulation function, no active bleeding or thrombotic disorders, (9) those who voluntary participation in the study, signed informed consent, (10) those who expected good compliance, able to follow-up on efficacy and adverse reactions as required by the protocol.

•(1) patients with clinical symptoms of brain metastases, (2)those with other untreated malignancies, (3)those with dMMR for immunohistochemistry or MSI-H for genetic testing, (4) those with uncontrollable hypertension, (5) those with uncontrollable clinical cardiac symptoms or disease, (6) those with multiple factors that affect the absorption of oral medications, such as inability to swallow and intestinal obstruction (7)those at risk of bleeding, including the following: a. active peptic ulcer lesions; b. history of black stools and vomiting of blood within 3 months; c. hemoptysis within 1 month before study entry; (8) those who have major surgery, open biopsy, or significant trauma within 28 days before enrollment, (9) those who will be, or are, participating in other clinical trials (10) those who with other conditions such as pregnancy that researchers consider unsuitable for inclusion.

发起方

Xi yuan Hospital of CACMS